Current Studies

The Research Department is currently conducting studies in the following areas:

GS-5745 in Crohn’s disease

Dietzia C79793-74 in Crohn’s disease

Ustekinumab CNTO1275 in Ulcerative Colitis

If you are interested in more information about the studies listed above, or would like to know about upcoming studies please call us on (02) 9713 4011

Get Adobe Acrobat Reader Trust Mark

Department of Research and Innovation

Current Studies

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohn’s Disease
Status: Recruiting now
ClinicalTrial.gov Identifier: NCT02405442
Aim: To evaluation the safety and efficacy of GS-5745 in adults with active Crohn’s disease.

Single centre, open label Phase 1/Phase 2 study to evaluate the safety and efficacy of Dietzia C79793-74 in moderate to severe Crohn’s disease
Status: Enrolling by invitation only
ANZCTR Trial ID: ACTRN12614000465651
Aim: To see if treatment with Dietzia C79793-74 in patients with Crohn’s disease is safe and effective in reducing disease severity and improving quality-of-life.

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.
Status: Recruiting now
ANZCTR Trial ID: NCT02407236
Aim: To evaluation the safety and efficacy of intravenous (IV) ustekinumab in inducing clinical remission in subjects with moderately to severely active Ulcerative Colitis.

If you would like more information, please call us on (02) 9713 4011 and follow the prompts for the Research Department.

 

 


CDD